Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for prevention of postoperative fever after TACE in hepatocellular carcinoma
ChiCTR-IPR-17010323Phase 4Recruiting
- Sponsor
- Lishui City Central Hospital
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of celecoxib in hepatocellular carcinoma (HCC) and Postoperative fever (POF) (2 arms), sponsored by Lishui City Central Hospital. Primary endpoints: Quality of life and Safety. Started Jan 2017; status: recruiting.
02
Drugs
celecoxib
03
Conditions
hepatocellular carcinoma (HCC)Postoperative fever (POF)
Beyond the preview
Go deeper on ChiCTR-IPR-17010323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010323.